• Citer

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

par Baselga, José;Ito, Yoshinori;Awada, Ahmad ;Chia, Stephen;Jagiełło-Gruszfeld, Agnieszka;Pistilli, Barbara;Tseng, Ling Ming;Hurvitz, Sara;Masuda, Norikazu;Takahashi, Masato;Vuylsteke, Peter;Im, Seock Ah;Hachemi, Soulef;Dharan, Bharani;Di Tomaso, Emmanuelle;Urban, Patrick;Massacesi, Cristian;Campone, Mario;Iwata, Hiroji;Cortes, Javier;De Laurentiis, Michele;Jiang, Zefei;Arteaga, Carlos C.L.;Jonat, Walter;Clemons, Mark J
Référence Lancet oncology, 18, 7, page (904-916)
Publication Publié, 2017-07

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Auteur:	Baselga, José; Ito, Yoshinori; Awada, Ahmad; Chia, Stephen; Jagiełło-Gruszfeld, Agnieszka; Pistilli, Barbara; Tseng, Ling Ming; Hurvitz, Sara; Masuda, Norikazu; Takahashi, Masato; Vuylsteke, Peter; Im, Seock Ah; Hachemi, Soulef; Dharan, Bharani; Di Tomaso, Emmanuelle; Urban, Patrick; Massacesi, Cristian; Campone, Mario; Iwata, Hiroji; Cortes, Javier; De Laurentiis, Michele; Jiang, Zefei; Arteaga, Carlos C.L.; Jonat, Walter; Clemons, Mark J
Informations sur la publication:	Lancet oncology, 18, 7, page (904-916)
Statut de publication:	Publié, 2017-07
Sujet CREF:	Cancérologie
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1470-2045
	info:doi/10.1016/S1470-2045(17)30376-5
	info:pii/S1470204517303765
	info:scp/85020030586
	info:pmid/28576675